Skip to main content
. 2015 Mar 25;6(11):9564–9576. doi: 10.18632/oncotarget.3259

Table 2. Genotypes of MTRR, MTHFR, MTR and TS polymorphisms and gastric cancer patients’ survival.

Genetic model Genotypes patients Deaths MST (months) log-rank P HR (95%CI)a
MTRR rs1801394 A66G
Codominant model AA 489 242 51 0.014 1.00
GA 347 151 80 0.838(0.684–1.028)
GG 49 14 87b 0.500(0.291–0.856)
Dominant model AA 489 242 51 0.022 1.00
GA/GG 396 165 97 0.793(0.651–0.967)
Recessive model AA/GA 836 393 65 0.019 1.00
GG 49 14 87b 0.537(0.315–0.915)
MTHFR rs1801131 A1298C
Codominant model AA 640 301 65 0.090 1.00
CA 236 110 63 0.985(0.792–1.225)
CC 28 7 81b 0.444(0.210–0.940)
Dominant model AA 640 301 65 0.429 1.00
CA/CC 264 117 89 0.918(0.742–1.137)
Recessive model AA/CA 876 411 65 0.042 1.00
CC 28 7 81b 0.446(0.211–0.942)
MTHFR rs1801133 C677T
Codominant model CC 313 151 60 0.793 1.00
TC 438 200 78 0.940(0.761–1.161)
TT 141 63 63 0.918(0.684–1.231)
Dominant model CC 313 151 60 0.51 1.00
TC/TT 579 263 74 0.935(0.766–1.143)
Recessive model CC/TC 751 351 65 0.708 1.00
TT 141 63 63 0.951(0.727–1.244)
MTR rs1805087 A2756G
Codominant model AA 684 314 52 0.041 1.00
GA 149 69 88 1.033(0.796–1.341)
GG 7 0 75b 0
Dominant model AA 688 317 67 0.038 1.00
GA/GG 149 69 70 0.972(0.749–1.261)
Recessive model AA/GA 830 386 65 0.053 1.00
GG 7 0 75b 0.049(0.001–3.620)
TYMS 5-UTR 2R > 3R
Codominant model 2R2R 43 24 35 0.279 1.00
2R3R 276 113 70 0.807(0.522–1.248)
3R3R 51 27 78 0.732(0.481–1.115)
Dominant model 2R/2R 43 24 35 0.184 1.00
2R3R/3R3R 794 357 74 0.758(0.501–1.146)
Recessive model 2R2R/2R3R 319 154 62 0.216 1.00
3R3R 518 227 78 0.880(0.717–1.080)
TYMS 3-UTR 6bp ins/del
Codominant model I/I 61 30 46 0.682 1.00
D/I 410 193 63 0.948(0.645–1.393)
D/D 413 187 77 0.880(0.598–1.294)
Dominant model I/I 61 30 46 0.63 1.00
DI/DD 823 380 70 0.913(0.630–1.324)
Recessive model II/DI 471 223 63 0.407 1.00
D/D 413 187 77 0.922(0.759–1.119)
a

Adjusted for age and sex.

b

Mean survival time was provided when MST could not be calculated.